Illumina (NASDAQ:ILMN) had its price target reduced by analysts at Deutsche Bank from $290.00 to $280.00 in a research note issued to investors on Friday, BenzingaRatingsTable reports. The brokerage presently has a “hold” rating on the life sciences company’s stock. Deutsche Bank’s price objective suggests a potential downside of 8.21% from the company’s current price.
Several other research analysts have also recently commented on ILMN. Bank of America assumed coverage on shares of Zai Lab in a research report on Friday. They issued a “buy” rating for the company. Zacks Investment Research cut shares of GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 2nd. Wolfe Research assumed coverage on shares of Waters in a research report on Thursday, May 30th. They issued an “underperform” rating for the company. Canaccord Genuity restated a “buy” rating and issued a $360.00 target price (up previously from $350.00) on shares of Illumina in a research report on Monday, June 10th. Finally, OTR Global cut shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $341.15.
Shares of NASDAQ:ILMN opened at $305.05 on Friday. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. Illumina has a fifty-two week low of $268.62 and a fifty-two week high of $380.76. The firm’s 50-day simple moving average is $344.09. The company has a market cap of $53.46 billion, a P/E ratio of 53.33, a PEG ratio of 2.53 and a beta of 1.15.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 23.49%. The business had revenue of $846.00 million during the quarter, compared to the consensus estimate of $838.70 million. During the same quarter in the prior year, the firm earned $1.45 EPS. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. As a group, analysts expect that Illumina will post 6.68 earnings per share for the current fiscal year.
In other news, Director Frances Arnold sold 1,503 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $307.95, for a total value of $462,848.85. Following the completion of the transaction, the director now directly owns 10,159 shares in the company, valued at $3,128,464.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total transaction of $38,659.48. Following the completion of the transaction, the senior vice president now owns 8,086 shares of the company’s stock, valued at $2,520,972.22. The disclosure for this sale can be found here. Insiders sold 59,291 shares of company stock valued at $19,459,234 over the last quarter. Insiders own 0.38% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Massmutual Trust Co. FSB ADV lifted its stake in Illumina by 83.0% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the last quarter. Strategy Asset Managers LLC acquired a new stake in Illumina during the first quarter valued at approximately $26,000. Financial Advocates Investment Management lifted its stake in Illumina by 1,430.0% during the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock valued at $28,000 after purchasing an additional 572 shares during the last quarter. C J Advisory Inc acquired a new stake in Illumina during the first quarter valued at approximately $29,000. Finally, Lake Point Wealth Management acquired a new stake in Illumina during the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 89.69% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: What is a Lock-Up Period?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.